Prostate Cancer Theranostics

Toward Theranostics of Aggressive Prostate Cancer

Retraction of “Tunable Plasmonic Nanoprobes for Theranostics of Prostate Cancer”

Theranostic applications require coupling of diagnosis and therapy, a high degree of specificity and adaptability to delivery methods compatible with clinical practice. The tunable physical and biological effects of selective targeting and activation of plasmonic nanobubbles (PNB) were studied in a heterogeneous biological microenvironment of prostate cancer and stromal cells. All cells were ta...

Cancer Theranostics: An Introduction

Theranostics is a portmanteau of therapeutics and diagnostics. It can be diagnosis followed by therapy to stratify patients who will likely respond to a given treatment. It can also be therapy followed by diagnosis to monitor early response to treatment and predict treatment efficacy. It is also possible that diagnostics and therapeutics are codeveloped. For example, nanoplatforms can be design...

Magnetic Nanoparticles in Cancer Theranostics

In a report from 2008, The International Agency for Research on Cancer predicted a tripled cancer incidence from 1975, projecting a possible 13-17 million cancer deaths worldwide by 2030. While new treatments are evolving and reaching approval for different cancer types, the main prevention of cancer mortality is through early diagnosis, detection and treatment of malignant cell growth. The las...

MicroRNAs as Biomarkers for Diagnosis, Prognosis and Theranostics in Prostate Cancer.

Prostate cancer (PC) includes several phenotypes, from indolent to highly aggressive cancer. Actual diagnostic and prognostic tools have several limitations, and there is a need for new biomarkers to stratify patients and assign them optimal therapies by taking into account potential genetic and epigenetic differences. MicroRNAs (miRNAs) are small sequences of non-coding RNA regulating specific...